One RFA is a Research Funding Award launched by the ACTION Consortium, an international collaboration that has the ambition to find innovative approaches to tackle neuroblastoma.

The call is focused on refractory and relapsed neuroblastoma, calling for innovative approaches to accelerating clinical trials, and evaluation of novel therapies. By pooling our resources to form the ACTION Consortium, this award will be one of the largest seen in the neuroblastoma field, standing at $2 million.

Founded by five non-profit organisations, Anticancer Fund (Belgium), The Evan Foundation (United States), Kindred Foundation (Canada), Solving Kids’ Cancer (United Kingdom) and Zoé4Life (Switzerland), the ACTION Consortium is a collective force committed to Advancing Clinical Trial Implementation and Optimisation in Neuroblastoma.